

Dolutegravir versus Raltegravir in Treatment Experienced
SAILING Study

Dolutegravir versus Raltegravir in Treatment Experienced SAILING: Study Design

Study Design: SAILING


- **Background:** Randomized, double-blind, active-control phase 3 trial evaluating efficacy, safety, and emergent resistance with dolutegravir versus raltegravir in antiretroviral-experienced, integrase inhibitor-naïve persons with HIV who have at least 2-class resistance.
- **Inclusion Criteria (n = 715)**
 - Age ≥ 18 years
 - Resistance to ≥ 2 ARV classes
 - Integrase inhibitor-naïve
 - 2 consecutive HIV RNA ≥ 400 copies/mL (unless $> 1,000$ copies/mL at screening)
- **Treatment Arms**
 - Dolutegravir + up to 2 background ARTs
 - Raltegravir + up to 2 background ARTs

**Dolutegravir 50 mg QD +
 ≤ 2 Background ART Drugs**
(n = 354)

**Raltegravir 400 mg BID +
 ≤ 2 Background ART Drugs**
(n = 361)


Dolutegravir versus Raltegravir in Treatment Experienced SAILING: Results

Week 48 Virologic Response, By Baseline HIV RNA Level



Dolutegravir versus Raltegravir in Treatment-Experienced SAILING: Results

Week 48 Virologic Failure



VF = Virologic Failure

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study: Conclusion

Interpretation: “Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

